** Shares of drug developer Ideaya Biosciences IDYA.O fall 4.6% to $20.94
** Co reports Q4 net loss of $130.3 million compared with net loss of $34.0 million a year ago
** Collaboration revenue for the quarter was $7 million compared to $3.9 million a year earlier
** Co received milestone payment from GSK GSK.L
** As of December 31, co had cash, cash equivalents and marketable securities of about $1.1 billion, compared to $632.6 million a year earlier
** Separately, co entered into an additional clinical study collaboration and supply agreement with Gilead Sciences GILD.O to test IDYA's experimental drug, IDE397, in combination with GILD's trodelvy to treat a type of lung cancer
** In the last 12 months, IDYA has fallen ~53%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。